Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Sets 2020 Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 07:40am EDT

By Dave Sebastian

Bristol-Myers Squibb Co. (BMY) on Thursday set its financial outlook for 2020 as it reported fourth-quarter loss and higher sales.

The pharmaceutical company expects 2020 revenue of $40.5 billion to $42.5 billion both on a reported and adjusted basis.

It sees earnings of 75 cents a share to 95 cents a share, or $6 a share to $6.20 a share on an adjusted basis.

The company said its guidance for 2020 and 2021 includes the effect of the Celgene acquisition and the Otezla divestiture.

Shares rose 1.1% in premarket trading.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 4.21% 57.87 Delayed Quote.-9.85%
CELGENE 0.10% 108.24 Delayed Quote.68.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BRISTOL-MYERS SQUIBB COMPA
10:32aACCELERON PHARMA : Bristol-Myers Shares Up After New FDA Nod for Reblozyl
DJ
05:25aBRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Reblozyl, the ..
AQ
04/03BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Approves Reblozyl..
BU
04/02BRISTOL-MYERS SQUIBB COMPANY : Ex-dividend day for
FA
04/01BRISTOL MYERS SQUIBB : and bluebird bio Announce Submission of Biologics License..
AQ
03/31BRISTOL MYERS SQUIBB : Bluebird Submit Biologics License Application for Idecabt..
DJ
03/31BRISTOL MYERS SQUIBB : and bluebird bio Announce Submission of Biologics License..
BU
03/31CYTOMX THERAPEUTICS : Announces Milestone Achievement in AbbVie CD71 Partnership..
AQ
03/30BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of Z..
AQ
03/27BRISTOL MYERS SQUIBB : Myers Gets Positive CHMP Opinion for Zeposia
DJ
More news
Financials (USD)
Sales 2019 26 418 M
EBIT 2019 8 540 M
Net income 2019 -
Debt 2019 40 977 M
Yield 2019 3,00%
P/E ratio 2019 -
P/E ratio 2020 60,0x
EV / Sales2019 6,28x
EV / Sales2020 3,56x
Capitalization 125 B
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 69,36  $
Last Close Price 55,21  $
Spread / Highest target 43,1%
Spread / Average Target 25,6%
Spread / Lowest Target -9,44%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Michael Grobstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-9.85%126 110
JOHNSON & JOHNSON-8.02%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075